Join to view full profile
2316 E Meyer Blvd# 1EKansas City, MO 64132
Phone+1 816-974-5050
Dr. LaPelusa is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Michael LaPelusa, MD, is based in Kansas City and currently serves as a Hematologist/Oncologist at MidAmerica Cancer Care. Dr. LaPelusa completed a residency in Internal Medicine at Vanderbilt University Medical Center from 2020 to 2023, followed by a fellowship in Hematology and Medical Oncology at the University of Texas MD Anderson Cancer Center from 2023 to 2026. Dr. LaPelusa has contributed to the field through several publications, including recent works featured in The Oncologist, The Lancet Digital Health, and Nature Communications. He also writes on multi-cancer early detection testing at beforestageone.com.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2023 - 2026
Vanderbilt University Medical CenterResidency, Internal Medicine, 2020 - 2023
University of Texas Rio Grande Valley School of MedicineClass of 2020, M.D.
Certifications & Licensure
KS State Medical License 2026 - 2027
MO State Medical License 2026 - 2027
TX State Medical License 2024 - 2027
TN State Medical License 2022 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal MedicineInternal Medicine
Publications & Presentations
PubMed
- Patterns of progression and survival in patients with mismatch repair deficient/ microsatellite instability- high metastatic colorectal cancer treated with immunotherapy.Michael LaPelusa, Preksha Shah, Deepak Bhamidipati, Naishu Kui, Alisha Bent
The Oncologist. 2026-07-08 - The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study.Mathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, Ciro Celsa
The Lancet. Digital Health. 2026-02-01 - 8 citationsLong-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors.Michael LaPelusa, Wei Qiao, Bryan Iorgulescu, Francis San Lucas, Keyur Patel
Nature Communications. 2025-05-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
